Treats mild to moderate dementia of the Alzheimer’s type. ANDA 78185, held by Hikma Pharmaceuticals. Galantamine Hydrobromide.
As of Nov 21, 2026, ANDA 78185 (Galantamine Hydrobromide), held by Hikma Pharmaceuticals, was first approved by FDA on Jan 30, 2009, with 6 approved supplements and 0 published complete response letters.
Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer’s type.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 30, 2009 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Galantamine Hydrobromide4MG/ML · solution;oral | Galantamine Hydrobromide | Rx |
| Nov 2, 2023 | Supplement 8Manufacturing | Approved | None posted |
| Jul 17, 2018 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 17, 2018 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 17, 2015 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 17, 2015 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 17, 2015 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 30, 2009 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters